Parathyroid Hormone (PTH) and Romosozumab
Teriparatide (recombinant human PTH, Forsteo™) is the first of the bone-forming agents and has been approved in Europe and in the USA for treatment of postmenopausal osteoporosis and recently also of osteoporosis in men, with a treatment duration of 18 (Europe) and 24 months (USA).PTH first stimulates bone formation followed by an increase in bone …